Fitch: Boston Scientific unchanged

Fitch Ratings said it the ratings and stable outlook of Boston Scientific Corp. will not be affected by the recent jury verdict in favor of a Johnson & Johnson claim that its stents infringe on patents.

Boston Scientific has already stated its intention to appeal the verdict and any potential award, the agency added.

The company's ratings reflect a strong credit profile, leading market positions and robust cash generation offset by product concentration and litigation risks, Fitch said, adding that for the past 12 months ended March 31, its coverage (EBITDA/interest) was 30.6 times and leverage (total debt/EBITDA) 0.7 times.

Fitch said its rating on the company include the senior unsecured notes at A, $2.165 billion unsecured bank credit facility at A and F1 commercial paper.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.